Trials / Recruiting
RecruitingNCT06557148
A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer
18F-Fluoroestradiol (FES) Positron Emission Tomography for the Detection and Treatment Response Monitoring in Patients With Metastatic Lobular Breast Carcinoma
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study to compare two types of cancer imaging scans to see which is better at detecting and monitoring metastatic ILC. This study will compare PET/CT (positron emission tomography/computed tomography) scans using the radiotracer fluorine 18 (18F)-fluoroestradiol (FES) with a standard imaging approach for detecting and monitoring ILC, PET/CT scans using the radiotracer 18F-fluorodeoxyglucose (FDG). These scans will be referred to as FES PET/CT scans and FDG PET/CT scans.
Conditions
- Breast Cancer
- Lobular Breast Carcinoma
- Breast Carcinoma
- Metastatic Breast Cancer
- Metastatic Lobular Breast Carcinoma
- Metastatic Breast Carcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | 18F-Fluoroestradiol PET/CT | Scanned at baseline and again posttreatment within 2 weeks of the restaging FDG PET/CT |
Timeline
- Start date
- 2024-08-13
- Primary completion
- 2027-08-13
- Completion
- 2027-08-13
- First posted
- 2024-08-16
- Last updated
- 2026-02-27
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT06557148. Inclusion in this directory is not an endorsement.